Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19801616 | 0.93 | FEN1 (0.49) | FEN1ALOX5APALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19804590 | 0.90 | FEN1 (0.53) | FEN1ALOX5APALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19804192 | 0.86 | FEN1 (0.41) | FEN1ALOX5APALDH1A1KDM4ECYP11B1 | |
| SCHEMBL19796940 | 0.85 | RARB (0.48) | FEN1ALOX5APALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL19804421 | 0.85 | FEN1 (0.43) | FEN1ALOX5APALDH1A1 | |
| SCHEMBL19804540 | 0.84 | FEN1 (0.47) | FEN1ALOX5APALDH1A1 | |
| SCHEMBL19804168 | 0.84 | SLC6A9 (0.40) | FEN1ALOX5APALDH1A1KDM4ECYP11B1 | |
| SCHEMBL19804534 | 0.82 | FFAR1 (0.38) | ALDH1A1SMN1; SMN2MEN1KMT2AFFAR4 | |
| SCHEMBL19804308 | 0.82 | ALOX5AP (0.40) | FEN1ALOX5APALDH1A1KDM4EMEN1 | |
| SCHEMBL19804410 | 0.82 | ALOX5AP (0.43) | FEN1ALOX5APALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FEN1 2669/4885ALOX5AP 2507/4885ALDH1A1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.